[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Sasaki H, Ohara N, Minamikawa T, Umeda M, Komori T, Kojima N, Takemura N, Morita H, Sugihara R, Enoki E, Itoh T: Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report). Kobe J Med Sci; 2008;54(3):E174-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival metastasis from ovarian mucinous cystadenocarcinoma as an initial manifestation (a rare case report).
  • Most metastatic tumors have the propensity for involving the mandible rather than the oral soft tissues.
  • Herein, we describe an unusual case of ovarian mucinous cystadenocarcinoma that metastasized to the mandibular gingiva as an initial manifestation.
  • There is little information regarding metastatic ovarian cancer to the oral cavity.
  • A patient was a 54-year-old woman who developed the paresthesia and swelling of the right mandible after tooth extraction.
  • A biopsy taken from the gingiva showed mucinous adenocarcinoma, indicating the gingival metastasis of undiscovered primary cancer.
  • A positron emission tomography and computed tomography using 18F-fluorodeoxyglucose depicted an ovarian tumor with multiple pelvic and paraaortic lymph node swellings.
  • A magnetic resonance imaging (MRI) clearly demonstrated the presence of an ovarian cancer.
  • Based on the imaging studies, the diagnosis of the gingival metastasis of an ovarian cancer was suspected.
  • The histology of surgical specimen confirmed the gingival metastasis of ovarian mucinous adenocarcinoma.
  • She has been treated with adjuvant chemotherapy consisting of paclitaxel and carboplatin.
  • This case emphasizes that although rare, metastatic ovarian cancer to the gingiva should be included in the differential diagnosis of tumors in the oral cavity.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / pathology. Gingival Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Biopsy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Positron-Emission Tomography. Radiography, Panoramic. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246966.001).
  • [ISSN] 1883-0498
  • [Journal-full-title] The Kobe journal of medical sciences
  • [ISO-abbreviation] Kobe J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Kurokawa T, Yoshida Y, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F: Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer; 2004 May 10;109(6):926-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
  • We evaluated whether tracer FDG uptake, quantified as an SUV by PET in ovarian epithelial tumors, correlates with clinical stage, tumor grade, cell proliferation and glucose metabolism, all of which are biomarkers for response to chemotherapy, prognosis and overall survival in ovarian cancer patients.
  • Seventeen patients suspected of having ovarian cancer by physical examination, tumor marker analysis and anatomic imaging (such as sonography, CT and/or MRI) underwent whole-body FDG-PET within the 2 weeks prior to surgery.
  • Seventeen epithelial ovarian tumor specimens (13 malignant tumors, 5 at stage I, 2 at stage II, 6 at stage III; 2 borderline tumors; and 2 benign lesions) were available for pathologic evaluation.
  • Therefore, glucose consumption, as determined by analysis of SUVs in FDG-PET, may be a noninvasive biomarker for ovarian epithelial tumors.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Ki-67 Antigen / metabolism. Monosaccharide Transport Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / radionuclide imaging. Biomarkers, Tumor. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radionuclide imaging. Cell Division. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radionuclide imaging. Female. Glucose / metabolism. Glucose Transporter Type 1. Humans. Neoplasm Staging. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15027127.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Ki-67 Antigen; 0 / Monosaccharide Transport Proteins; 0 / Radiopharmaceuticals; 0 / SLC2A1 protein, human; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


3. Milenković V, Sparić R, Dokić M, Petković S, Atanacković J: [Ovarian cancer after in vitro fertilization]. Srp Arh Celok Lek; 2004 Sep-Oct;132(9-10):331-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cancer after in vitro fertilization].
  • There is serious concern about cancer risk in women undergoing ovarian stimulation treatment for infertility and longterm safety of these procedures.
  • Association between fertility drugs and ovarian cancer is still controversial.
  • A 30-year-old woman was referred to our institution with the initial diagnosis of an adnexal tumor after in vitro fertilization.
  • Her history revealed adnexectomy for mucinous cystadenofibroma of the left ovary eight years ago, and cystectomy due to cystadenoma of the right ovary three years ago.
  • Broad spectrum antibiotic treatment was initiated.
  • Pathological diagnosis was mucinous ovarian adenocarcinoma.
  • After the surgery, chemotherapy was applied.
  • There is an urgent need for clear interpretation of the association between fertility drugs and subsequent higher ovarian cancer risk.
  • Lacking conclusive evidence, an increased risk of ovarian cancer has been reported and more recently disputed.
  • Higher ovarian cancer risk may be serious and even life-threatening complication for women undergoing ovarian stimulation.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / chemically induced. Fertility Agents, Female / adverse effects. Fertilization in Vitro / adverse effects. Ovarian Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794056.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Fertility Agents, Female
  •  go-up   go-down


Advertisement
4. Yokoyama Y, Kaji H, Kondoh H, Takeuchi E, Yamasaki Y, Inui Y: Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin. Gynecol Obstet Invest; 2001;52(3):210-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • BACKGROUND: The survival rate of patients with advanced-stage mucinous cystadenocarcinoma of the ovary is dismal and no best treatment is known.
  • We report a case of complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin.
  • CASE: A 51-year-old nullipara diagnosed with International Federation of Gynecology and Obstetrics stage IV mucinous cystadenocarcinoma of the ovary underwent cytoreductive surgery followed by systemic chemotherapy employing paclitaxel and carboplatin every 4 weeks for 3 courses.
  • The patient tolerated chemotherapy well, demonstrated a remarkable response showing no evidence of malignancy at a second-look laparotomy.
  • As a consolidation chemotherapy after negative second-look laparotomy, she underwent another three courses of chemotherapy of the same regimen, and is showing no evidence of disease.
  • CONCLUSION: Paclitaxel and carboplatin may be effective in treating mucinous cystadenocarcinoma of the ovary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11598367.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA, Taylor PT Jr: Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol; 2006 Aug;195(2):568-74; discussion 574-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.
  • OBJECTIVE: The purpose of this study was to evaluate differences in morbidity, progression-free interval, and survival in women with advanced epithelial ovarian cancer treated with initial chemotherapy versus initial surgery.
  • STUDY DESIGN: All women with epithelial ovarian cancer who were treated surgically at our hospital between January 1, 1995, and January 1, 2003, were eligible; the cases of 200 patients met the criteria and underwent retrospective chart review.
  • RESULTS: Ninety-eight patients (49%) had initial chemotherapy, and 102 patients (51%) had initial surgery.
  • Patients who received initial chemotherapy were more likely to have stage IV disease (initial chemotherapy, 27%, vs initial surgery, 8%; P = .042) and grade 3 disease (initial chemotherapy, 73%, vs initial surgery, 61%; P = .025).
  • Optimal cytoreduction was achieved more often in patients who received initial chemotherapy (initial chemotherapy, 86%, vs initial surgery, 54%; P < .001).
  • Only optimal cytoreduction (P = .022), and not treatment choice (P = .089), had an impact on median survival.
  • CONCLUSION: Initial chemotherapy is a reasonable alternative to initial surgery for the treatment of selected patients with advanced epithelial ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cystadenocarcinoma / drug therapy. Cystadenocarcinoma / surgery. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Comorbidity. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Survival Analysis


6. Sato S, Kobayashi Y, Okuma Y, Kondo H, Kanishi Y, Saito K, Kiguchi K: Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. Hum Cell; 2002 Sep;15(3):171-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
  • We recently established a cell line (designated 371M) derived from an ovarian mucinous cystadenocarcinoma.
  • Adjuvant chemotherapy (combined paclitaxel and carboplatin) was administered, but was ineffective, and she died about 4 months after surgery.
  • They proliferated in a monolayered sheet with doubling times of 84 h and 37 h in the 10th and 34th passages, respectively.
  • Sensitivity of 371M cells to a variety of anti-cancer drugs was examined by in vitro MTT assay, and the results suggested that CPT-11 and CDDP were more effective against 371M cells than other anti-cancer agents.
  • [MeSH-major] Camptothecin / analogs & derivatives. Cell Culture Techniques / methods. Cystadenocarcinoma, Mucinous. Ovarian Neoplasms
  • [MeSH-minor] Animals. Antigens, Tumor-Associated, Carbohydrate. Antineoplastic Agents / pharmacology. Biomarkers, Tumor. Cell Division. Cisplatin / pharmacology. Drug Screening Assays, Antitumor. Female. Humans. Karyotyping. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1231-7 [3319135.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1985 Sep;37(9):1820-4 [4056530.001]
  • [Cites] Hum Cell. 1990 Mar;3(1):52-6 [2083224.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(4):278-82 [11695809.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5153-61 [2548714.001]
  • [Cites] Hum Cell. 1995 Dec;8(4):189-94 [8721090.001]
  • [Cites] Gynecol Oncol. 1991 Feb;40(2):118-28 [2010102.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 [6891650.001]
  • [Cites] Hum Cell. 1997 Sep;10(3):199-208 [9436040.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3103-8 [8319218.001]
  • [Cites] Hum Cell. 1999 Dec;12(4):211-7 [10834108.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):826-32 [2981614.001]
  • [Cites] Jpn J Cancer Res. 1994 Dec;85(12):1247-56 [7852189.001]
  • [Cites] Cancer Chemother Rep. 1974 Mar-Apr;58(2):271-3 [4830501.001]
  • (PMID = 12703547.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0H43101T0J / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • Patients with ovarian cancer were followed up.
  • Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed.
  • EGFR was highly expressed in ovarian cancer patients at late stage (III-IV), with poor differentiation and ascites (P <0.05).
  • The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP (57.14% and 53.70%) than in those with negative expressions (P<0.05).
  • The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance (92.86% and 85.71%) than in those sensitive to chemotherapy (P<0.05).
  • The three-year survival rate of ovarian cancer patients was 53.00%.
  • Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time (P<0.01).
  • CONCLUSION: The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080004.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Doi D, Boh Y, Konishi H, Asakura H, Takeshita T: Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet; 2009 Oct;280(4):633-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
  • Combined chemotherapy using carboplatin and paclitaxel has been established as a standard regimen for epithelial ovarian carcinoma.
  • We present the case of a 36-year-old woman with ovarian mucinous cystadenocarcinoma who underwent exploratory laparotomy during pregnancy, revealing Stage 1c at gestational week 15.
  • Afterwards, five courses of paclitaxel and carboplatin chemotherapy were administered biweekly from gestational week 24.
  • No recurrent or metastatic lesions were found and outcomes for both mother and neonate have been satisfactory for 40 months since diagnosis of ovarian carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Carboplatin / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Infant, Newborn. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205713.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Huang HP, Fang CN, Kan YY: Chemotherapy for ovarian mucinous cystadenocarcinoma during pregnancy: a case report. Eur J Gynaecol Oncol; 2004;25(5):635-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for ovarian mucinous cystadenocarcinoma during pregnancy: a case report.
  • There is limited experience in the treatment of epithelial ovarian malignancy with chemotherapy during pregnancy.
  • We present the case of a 36-year-old women with ovarian mucinous cystadenocarcinoma during pregnancy, on whom exploratory laparotomy was performed at the gestational age of 16 weeks.
  • Afterwards chemotherapy with cyclophosphamide (500 mg/m2) and cisplatin (50 mg/m2) was administered beginning at the second trimester of pregnancy due to surgical Stage Ic.
  • Although preterm labor and a prematurely ruptured membrane occurred at the gestational age of 29 weeks before the fourth course of chemotherapy, there was still a satisfactory outcome for mother and fetus after an emergency cesarean section due to breech presentation at the gestational age of 30 weeks.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Female. Humans. Pregnancy. Pregnancy Trimester, Second

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493185.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


11. Tamiolakis D, Venizelos I, Nikolaidou S, Lambropoulou M, Bolioti S, Papadopoulos N: Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma. Cesk Patol; 2005 Apr;41(2):66-70
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and synchronous cervical squamous carcinoma.
  • Solid mural nodule within a mucinous cystic ovarian tumor occurs more often than generally presumed.
  • A 38-year-old woman underwent exploratory laparotomy for a right ovarian tumor.
  • After ovarian malignancy had been diagnosed from frozen section, the bilateral salpingo-oophorectomy and hysterectomy was performed.
  • The patient was treated with chemotherapy and radiotherapy.
  • The occurrence of ovarian mucinous cystadenocarcinoma with mural nodule of anaplastic carcinoma and cervical squamous cell carcinoma is evidently very uncommon, because we have not found a similar case in the literature.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966336.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. Shimada K, Iwase K, Aono T, Takeda S, Yoshida H, Koma M, Nomura M, Nishikawa K, Tamagawa H, Matsuda C, Fushimi H, Tanaka Y: A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine. Gan To Kagaku Ryoho; 2009 Jun;36(6):995-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine.
  • Mucinous cystic neoplasm(MCN)of the pancreas is a rare disease.
  • A distal pancreatectomy and a splenectomy were performed, and the resected specimen histologically revealed an invasive mucinous cystadenocarcinoma of the pancreas.
  • The postoperative computed tomography(CT)scan showed metastatic tumors of the Douglas pouch and the left ovary.
  • Gemcitabine(GEM)was thereafter systemically administered for palliative chemotherapy with a regimen of 1,000 mg/m / 2week for 3 weeks, followed by a week of rest.
  • When assessed by a CT scan after 4 courses of chemotherapy, marked shrinkage of the tumors was identified, and we could not detect the tumors clearly.
  • Therefore, systemic chemotherapy with GEM is considered to possibly be an effective treatment against MCN.
  • We describe herein the first case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to GEM and a brief review of the literature.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / pathology. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Peritoneum / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542723.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Friedrich M, Poleska W, Baltzer J, Salehin D: Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy.
  • : e16540 Background: Pseudomyxoma peritonei occurs mostly in conjunction with the type of intestinal mucinous borderline tumour and is characterized by building up a lot of mucus pour of cells.
  • The most common tumor is the pseudomyxoma peritoneii with mucinous borderline tumours of the ovaries or with mucinous tumours of the appendix, normally without showing a rupture of the ovarian tumour pre- or intraoperatively.
  • The diagnosis of pseudomyxoma peritonei is mainly difficult and guidelines for the treatment are unknown.
  • METHODS: In the period from 1991 to 2008, 52 patients with pseudomyxoma peritonei were treated by tumour debulking and intraoperative and intraperitoneal chemotherapy with Mitoxantron (40 mg in 300 ml of NaCl over 72 hours).
  • There were the following histologies: mucinous cystadenoma of the ovary n = 29, mucinous cystadenoma of the appendix n = 10, mucinous cystadenocarcinoma n = 13.
  • CONCLUSIONS: The instillation of mitoxantron intraperitoneally and intraoperatively is an effective and safe therapy without any side effects after maximal tumour debulking of pseudomyxoma peritoneii.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960827.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sayedur Rahman M, Al-Sibai MH, Rahman J, Al-Suleiman SA, El-Yahia AR, Al-Mulhim AA, Al-Jama F: Ovarian carcinoma associated with pregnancy. A review of 9 cases. Acta Obstet Gynecol Scand; 2002 Mar;81(3):260-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma associated with pregnancy. A review of 9 cases.
  • BACKGROUND: The purpose of this study was to review patients with ovarian cancer in pregnancy, the effectiveness of the available methods of treatment and their prognosis.
  • METHODS: A retrospective review of all women diagnosed to have cancer of the ovary associated with pregnancy who delivered at the authors' hospitals between January 1976 and December 2000.
  • The demography, clinical presentation, time and mode of diagnosis, treatment, pregnancy outcome and maternal survival were noted.
  • RESULTS: The incidence of ovarian carcinoma in pregnancy in the series was 0.08/1000 deliveries.
  • Of the 9 patients, 7 had epithelial cancers; 4 serous cystadenocarcinoma, 2 mucinous cystadenocarcinomas and one undifferentiated cancer.
  • Three patients had total abdominal hysterectomy, bilateral salpingo-oophorectomy and omentectomy followed by chemotherapy.
  • Debulking of the tumor was done in a patient in stage III with subsequent chemotherapy.
  • This patient died 13 months from the time of diagnosis of the tumor.
  • CONCLUSIONS: Association of ovarian cancer with pregnancy is a rare occurrence.
  • Early diagnosis and appropriate treatment offers the best prognosis for the patient.
  • Aggressive postoperative chemotherapy also contributed to the better outcome.
  • [MeSH-major] Carcinoma / complications. Carcinoma / therapy. Ovarian Neoplasms / complications. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / mortality. Pregnancy Complications, Neoplastic / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11966485.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 15
  •  go-up   go-down


15. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W: The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res; 2010;18(7):343-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
  • The role of estrogens in ovarian carcinogenesis and progression of ovarian cancer is unclear.
  • Cytochrome P450 is involved in estrogen metabolism, and polymorphisms have been associated with functional changes and risk for ovarian cancer.
  • In this study, we investigated the impact of the CYP1A1 Ile462Val polymorphism upon tumor risk and disease progression in ovarian cancer patients.
  • One hundred and eleven ovarian cancer patients who had been treated at the University Hospital of Essen between 1999 and 2007 and 119 age-matched healthy female controls were enrolled in this study.
  • The distribution of genotypes was statistically significant different between ovarian cancer patients and healthy controls.
  • We observed a significant association of the Ile allele with ovarian cancer (OR 2.6, 95% CI 1.5-4.7, p = 0.001).
  • Clinical parameters such as overall survival, FIGO stage, grading, and age at diagnosis did not differ significantly.
  • We observed a statistically significant association between the 462Val allele and platinum resistance, which was defined as a time interval < 6 months to disease progression after administration of a platinum-based primary chemotherapy (OR 5.9, 95% CI 1.5-23.2, p = 0.005).
  • We observed a significant association between the presence of the 462Ile allele with ovarian cancer.
  • While there is uncertainty about the potential involvement of CYP1A1 in the metabolism of platinum-containing agents, our findings suggest an association between the 462Val allele and the development of platinum resistance in ovarian tumors.
  • If confirmed in a larger, independent collective, our findings would have important relevance with respect to the clinical consequences for the primary chemotherapy of ovarian cancer patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytochrome P-450 CYP1A1 / genetics. Drug Resistance, Neoplasm / genetics. Organoplatinum Compounds / therapeutic use. Ovarian Neoplasms / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Female. Genotype. Humans. Middle Aged. Ovary / metabolism. Ovary / pathology. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377136.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


16. Buttarelli M, Houvenaeghel G, Lelièvre L, Jacquemier J, Guiramand J, Delpero JR: [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?]. Ann Chir; 2006 Oct;131(8):431-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pelvic posterior exenteration with immediate colo-rectal anastomosis: is it justified and feasible in advanced stage ovarian carcinoma?].
  • [Transliterated title] Une exentération pelvienne postérieure avec anastomose est-elle faisable et justifiée dans le traitement des cancers de l'ovaire à un stade évolué?
  • PURPOSE: The aim of this study is to show that the removal of the rectum is not an obstacle to implement an optimal surgery in advanced epithelial cancer of the ovary.
  • MATERIAL AND METHODS: Retrospective study on a population of 44 women with advanced epithelial cancer of the ovary.
  • This treatment was completed by chemotherapy for 36 of them.
  • The completion of chemotherapy started after an average of 5.2 weeks after surgery.
  • CONCLUSION: The posterior exenteration, when it's necessary, for advanced epithelial cancer of the ovary must not be an obstacle to obtain an optimal surgery.
  • This surgical act is safe for the management of this pathology without delaying the others therapeutics and allowing a satisfactory quality of life.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Endometrioid / surgery. Carcinosarcoma / surgery. Colon / surgery. Ovarian Neoplasms / surgery. Pelvic Exenteration. Rectum / surgery
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Colostomy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Cystectomy. Feasibility Studies. Female. Humans. Hysterectomy. Ileostomy. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Ovary / pathology. Preoperative Care. Quality of Life. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707093.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. Mecke H, Börner-Klaussner B, Grosse G, Nadjari B, Hauptmann S: [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy]. Zentralbl Gynakol; 2000;122(5):274-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
  • [Transliterated title] Zum klinischen Verhalten von serösen und muzinösen Borderline-Tumoren des Ovars mit diploider DNA-Stammlinie. Verlaufsbeobachtungen nach organerhaltender und nicht-organerhaltender Therapie.
  • Even today, the situation is still unclear with regard to the radicality of the operation and any adjuvant therapy required in treatment of borderline tumors of the ovary.
  • In the last two decades, treatment of these tumors in the Department of Gynecology and Obstetrics at our hospital has depended on the stage of the disease and the age of the patient.
  • From the end of 1985 to the end of 1992, 35 patients with borderline tumors of the ovaries were operated on.
  • Histologically, 14 borderline tumors were mucinous, 21 were serous.
  • Only one patient received adjuvant chemotherapy.
  • Later, these could no longer be demonstrated (one patient) or did not affect the survival time (three patients) and thus ultimately was not pathologically relevant.
  • It is not possible to make a definitive treatment recommendation on the basis of this investigation because the number of patients followed up was too small.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. DNA, Neoplasm / genetics. Diploidy. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy. Precancerous Conditions / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Follow-Up Studies. Humans. Laparoscopy. Middle Aged. Neoplasm Staging. Ovary / pathology. Prognosis. Reoperation

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857214.001).
  • [ISSN] 0044-4197
  • [Journal-full-title] Zentralblatt für Gynäkologie
  • [ISO-abbreviation] Zentralbl Gynakol
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


18. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and prognosis of mucinous tumors of the ovary.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • In this study, we compared the clinical characteristics and prognosis among these 3 types of mucinous tumors.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • All patients were reviewed by two pathologists, then the mixed type and cases showing other organized malignant tumors were excluded from this study.
  • Patients with mucinous carcinoma staged Ib or more were treated postoperatively with 6 cycles of platinum-based chemotherapy.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


19. Costa MJ, Hansen CL, Holden JA, Guinee D Jr: Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol; 2000 Jul;19(3):248-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum.
  • We test the hypothesis that the percentage of TopoIIa immunoreactive nuclei (TopoIIaI) aids in the treatment and prognostic evaluation of ovarian and primary peritoneal surface epithelial neoplasms (SENs) and correlates with established cell cycle control markers: p53, p21WAF1/CIP1 (p21), and Ki67.
  • TopoIIaI correlated with SEN architectural/nuclear grade (p < 10(-5)/10(-7)), but not histologic type.
  • The patients in this retrospective series of SEN were treated primarily with platinum-based chemotherapy.
  • These data may suggest further prospective studies in which patients with SENs exhibiting high TopoIIaI are treated with chemotherapy targeted against TopoIIa (e.g., etoposide).
  • In this retrospective series, high SEN TopoIIaI predicted poor survival when treated with platinum-based chemotherapy, which does not target TopoIIa.
  • [MeSH-major] Biomarkers / analysis. Cell Cycle. DNA Topoisomerases, Type II / analysis. Ovarian Neoplasms / enzymology. Peritoneal Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / enzymology. Cell Nucleus / pathology. Cystadenocarcinoma, Serous / enzymology. Cystadenocarcinoma, Serous / pathology. Endometrium / pathology. Female. Humans. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907174.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


20. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G: p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol; 2000 Dec;17(6):1231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21WAF1/CIP1 protein expression in primary ovarian cancer.
  • p21WAF1/CIP1 protein is a cyclin-dependent kinase inhibitor, able to prevent the CDK2/cyclin E induced retinoblastoma protein (pRB) phosphorylation, thus inhibiting cell cycle progression at G1 phase. p21WAF1/CIP1 protein levels were examined in a series of 102 ovarian tissue samples including normal ovary, primary ovarian tumors, omental metastasis, recurrent disease and residual tumor after chemotherapy exposure, by Western blot analysis.
  • The association of p21WAF1/CIP1 status with clinicopathological parameters and clinical outcome was also investigated. p21WAF1/CIP1 protein was detectable in 76 out of 102 (74%) ovarian tissue samples.
  • We observed a significant trend of p21 levels to gradually increase from normal ovarian tissues (median 0 a.u.) through primary ovarian cancers (median 0.19 a.u.
  • In the group of stage III-IV ovarian cancer patients, p21-positive cases showed a more favourable prognosis with respect to p21-negative cases: the 3-year time to progression (TTP) rate was 58% for p21-positive compared with 33% of p21-negative cases (p=0.036).
  • In conclusion, p21WAF1/CIP1 expression levels seem to be correlated with tumor status at the time of diagnosis and can predict TTP in a selected group of patients.
  • [MeSH-major] Cyclins / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Cell Cycle. Cisplatin / administration & dosage. Cyclin-Dependent Kinase Inhibitor p21. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Genes, p53. Humans. Life Tables. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Omentum. Ovary / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078810.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, Masucci GV: Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer. Gynecol Oncol; 2006 Oct;103(1):145-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
  • We have previously characterized a cluster of ovarian cancer patients with high incidence of HLA-A2.
  • METHODS: A population-based set of 97 patients with confirmed epithelial ovarian cancer were recorded in a database by age, histology, stage, surgery and treatment.
  • At the time the study was initiated, the majority of the patients were not alive and HLA-A2 expression was therefore determined by PCR/sequence-specific oligonucleotide hybridization using DNA extracted from paraffin-imbedded tissue specimens.
  • 44% were serous adenocarcinomas, 28% endometrioid, 6% mucinous, 13% clear cell carcinomas, 7% undifferentiated and 2% other epithelial tumors.
  • CONCLUSIONS: HLA-A2 is a negative factor for survival in women with serous adenocarcinomas of the ovary in stages III-IV.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. HLA-A2 Antigen / biosynthesis. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / immunology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / immunology. Cystadenocarcinoma, Serous / pathology. Female. Humans. Middle Aged. Neoplasm Staging. Paraffin Embedding. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542716.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-A2 Antigen
  •  go-up   go-down


22. Tang L, Zheng M, Xiong Y, Ding H, Liu FY: [Clinical characteristics and prognosis of epithelial ovarian cancer in young women]. Ai Zheng; 2008 Sep;27(9):951-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and prognosis of epithelial ovarian cancer in young women].
  • BACKGROUND & OBJECTIVE: Epithelial ovarian cancer mostly appears in aged women, but rarely in young women.
  • Little is known about the clinical characteristics and prognosis of epithelial ovarian cancer in women aged below 35 years.
  • This study was to evaluate the clinical characteristics, treatment, survival and prognosis of young patients with epithelial ovarian cancer.
  • METHODS: A total of 71 patients with confirmed epithelial ovarian cancer under the age of 35 years between Jun.1980 and Dec.
  • The tumor was located at one side of the ovary in 52 cases (73.2%).
  • Serous adenocarcinoma (40 cases, 56.3%) and mucinous adenocarcinoma (22 cases, 30.9%) were the most common pathologic types.
  • Sixty-eight patients received platinum and paclitaxel-based chemotherapy before or after operation.
  • Pathological grade and residual tumor size were independent prognostic factors affecting ovarian cancer.
  • CONCLUSIONS: Young women with epithelial ovarian cancer under the age of 35 years mostly have serous adenocarcinoma; tumors are normally unilateral; and the prognosis is good.
  • The ovarian function can be preserved in part of stage Ia and Grade I patients.
  • Pathological grade and residual tumor size are independent prognostic factors of epithelial ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Neoplasm Staging. Neoplasm, Residual / pathology. Ovariectomy. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate. Taxoids / therapeutic use. Tumor Burden. Young Adult


23. Morowitz M, Huff D, von Allmen D: Epithelial ovarian tumors in children: a retrospective analysis. J Pediatr Surg; 2003 Mar;38(3):331-5; discussion 331-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial ovarian tumors in children: a retrospective analysis.
  • BACKGROUND/PURPOSE: Epithelial tumors of the ovary account for about 15% of pediatric ovarian masses.
  • The authors reviewed a 14-year experience with ovarian masses to understand the spectrum of pathology, presentation, and outcome of children with epithelial lesions.
  • METHODS: All ovarian masses resected or biopsied at the authors' institution from 1988 to the present were reviewed retrospectively.
  • Patient age, presenting symptoms, operative procedures, postoperative treatment, and outcome were obtained from the medical record.
  • The histopathologic diagnoses for the epithelial tumors included 9 serous cystadenomas (47%) and 3 mucinous cystadenomas (16%), 3 mucinous cystadenocarcinomas (16%), and 4 serous tumors of borderline malignancy (21%).
  • Four patients (21%) underwent a subsequent laparotomy for either staging or recurrence, and 2 patients (11%) required chemotherapy.
  • One patient (5.3%) died of ovarian adenocarcinoma.
  • CONCLUSIONS: Epithelial tumors comprise a small but significant proportion of pediatric ovarian masses.
  • The pediatric surgeon must understand the biologic characteristics, operative management, and follow-up treatment of these tumors, and how these differ from germ cell lesions.
  • [MeSH-major] Ovarian Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cystadenocarcinoma, Mucinous / epidemiology. Cystadenoma, Mucinous / epidemiology. Cystadenoma, Serous / epidemiology. Cystectomy. Female. Germinoma / epidemiology. Humans. Hysterectomy. Neoplasms, Multiple Primary / epidemiology. Ovariectomy. Pennsylvania / epidemiology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12632344.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement